REFERENCES
2. Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557-88.
3. Treeprasertsuk S, Poovorawan K, Soonthornworasiri N, et al. A significant cancer burden and high mortality of intrahepatic cholangiocarcinoma in Thailand: a nationwide database study. BMC Gastroenterol. 2017;17:3.
4. Pupacdi B, Loffredo CA, Budhu A, et al; TIGER-LC Consortium. The landscape of etiological patterns of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in Thailand. Int J Cancer. 2024;155:1387-99.
5. Chaisaingmongkol J, Budhu A, Dang H, et al. Common molecular subtypes among Asian hepatocellular carcinoma and cholangiocarcinoma. Cancer Cell. 2017;32:57-70.e3.
6. Chan-On W, Nairismägi ML, Ong CK, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet. 2013;45:1474-8.
7. Jusakul A, Cutcutache I, Yong CH, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 2017;7:1116-35.
8. Hong JH, Yong CH, Heng HL, et al. Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies. Gut. 2024;73:966-84.
9. Raggi C, Taddei ML, Rae C, Braconi C, Marra F. Metabolic reprogramming in cholangiocarcinoma. J Hepatol. 2022;77:849-64.
10. Pastore M, Lori G, Gentilini A, et al. Multifaceted aspects of metabolic plasticity in human cholangiocarcinoma: an overview of current perspectives. Cells. 2020;9:596.
11. Yang F, Hilakivi-Clarke L, Shaha A, et al. Metabolic reprogramming and its clinical implication for liver cancer. Hepatology. 2023;78:1602-24.
12. Pant K, Richard S, Peixoto E, Gradilone SA. Role of glucose metabolism reprogramming in the pathogenesis of cholangiocarcinoma. Front Med. 2020;7:113.
13. Zhen Y, Liu K, Shi L, et al. FGFR inhibition blocks NF-ĸB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma. Nat Commun. 2024;15:3805.
14. Yang SM, Kim J, Lee JY, Lee JS, Lee JM. Regulation of glucose and glutamine metabolism to overcome cisplatin resistance in intrahepatic cholangiocarcinoma. BMB Rep. 2023;56:600-5.
15. Cao J, Zhang C, Jiang GQ, et al. Expression of GLS1 in intrahepatic cholangiocarcinoma and its clinical significance. Mol Med Rep. 2019;20:1915-24.
16. Xu L, Zhang Y, Lin Z, et al. FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma. J Hepatol. 2024;81:265-77.
17. Ruiz de Gauna M, Biancaniello F, González-Romero F, et al. Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids. Hepatology. 2022;76:1617-33.
18. Fu K, Yang X, Wu H, Gong J, Li X. Diabetes and PKM2 affect prognosis in patients with intrahepatic cholangiocarcinoma. Oncol Lett. 2020;20:265.
19. Saengboonmee C, Detarya M, Sangkhamanon S, Sawanyawisuth K, Seubwai W, Wongkham S. High glucose induced upregulation of cyclin a associating with a short survival of patients with cholangiocarcinoma: a potential target for treatment of patients with diabetes mellitus. Nutr Cancer. 2022;74:1734-44.
20. Osataphan S, Mahankasuwan T, Saengboonmee C. Obesity and cholangiocarcinoma: a review of epidemiological and molecular associations. J Hepatobiliary Pancreat Sci. 2021;28:1047-59.
21. Lee JW, Yoo ID, Hong SP, et al. Prognostic impact of visceral adipose tissue imaging parameters in patients with cholangiocarcinoma after surgical resection. Int J Mol Sci. 2024;25:3939.
22. Saengboonmee C, Seubwai W, Lert-Itthiporn W, Sanlung T, Wongkham S. Association of diabetes mellitus and cholangiocarcinoma: update of evidence and the effects of antidiabetic medication. Can J Diabetes. 2021;45:282-90.
23. Saengboonmee C, Seubwai W, Wongkham C, Wongkham S. Diabetes mellitus: possible risk and promoting factors of cholangiocarcinoma: association of diabetes mellitus and cholangiocarcinoma. Cancer Epidemiol. 2015;39:274-8.
24. Supabphol S, Seubwai W, Wongkham S, Saengboonmee C. High glucose: an emerging association between diabetes mellitus and cancer progression. J Mol Med. 2021;99:1175-93.
25. Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? J Hepatol. 2012;57:69-76.
26. Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol. 2020;72:95-103.
27. Sun H, Qi X. The role of insulin and incretin-based drugs in biliary tract cancer: epidemiological and experimental evidence. Discov Oncol. 2022;13:70.
28. Qi X, He P, Yao H, et al. Insulin therapy and biliary tract cancer: insights from real-world data. Endocr Connect. 2022;11:e210546.
29. Kinjo Y, Naito Y, Akiba J, et al. SUOX and GLUT1 are biomarkers for the prognosis in large duct type intrahepatic cholangiocarcinoma. Hum Pathol. 2022;128:11-9.
30. Thamrongwaranggoon U, Sangkhamanon S, Seubwai W, Saranaruk P, Cha'on U, Wongkham S. Aberrant GLUT1 expression is associated with carcinogenesis and progression of liver fluke-associated cholangiocarcinoma. In Vivo. 2021;35:267-74.
31. Kubo Y, Aishima S, Tanaka Y, et al. Different expression of glucose transporters in the progression of intrahepatic cholangiocarcinoma. Hum Pathol. 2014;45:1610-7.
32. Jóźwiak P, Krześlak A, Bryś M, Lipińska A. Glucose-dependent glucose transporter 1 expression and its impact on viability of thyroid cancer cells. Oncol Rep. 2015;33:913-20.
33. Phoomak C, Vaeteewoottacharn K, Silsirivanit A, et al. High glucose levels boost the aggressiveness of highly metastatic cholangiocarcinoma cells via O-GlcNAcylation. Sci Rep. 2017;7:43842.
34. Phoomak C, Vaeteewoottacharn K, Sawanyawisuth K, et al. Mechanistic insights of O-GlcNAcylation that promote progression of cholangiocarcinoma cells via nuclear translocation of NF-κB. Sci Rep. 2016;6:27853.
35. Zheng P, Pan HH, Zhou XH, et al. Glucose 6 phosphatase dehydrogenase (G6PD): a novel diagnosis marker related to gastrointestinal cancers. Am J Transl Res. 2023;15:2304-28.
36. Qu X, Sheng J, Shen L, et al. Autophagy inhibitor chloroquine increases sensitivity to cisplatin in QBC939 cholangiocarcinoma cells by mitochondrial ROS. PLoS One. 2017;12:e0173712.
37. Saengboonmee C, Seubwai W, Pairojkul C, Wongkham S. High glucose enhances progression of cholangiocarcinoma cells via STAT3 activation. Sci Rep. 2016;6:18995.
38. Detarya M, Thaenkaew S, Seubwai W, et al. High glucose upregulates FOXM1 expression via EGFR/STAT3 dependent activation to promote progression of cholangiocarcinoma. Life Sci. 2021;271:119114.
39. Saengboonmee C, Phoomak C, Supabphol S, et al. NF-κB and STAT3 co-operation enhances high glucose induced aggressiveness of cholangiocarcinoma cells. Life Sci. 2020;262:118548.
40. Saengboonmee C, Sorin S, Sangkhamanon S, et al. γ-aminobutyric acid B2 receptor: a potential therapeutic target for cholangiocarcinoma in patients with diabetes mellitus. World J Gastroenterol. 2023;29:4416-32.
42. Thompson CB, Vousden KH, Johnson RS, et al. A century of the Warburg effect. Nat Metab. 2023;5:1840-3.
43. Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029-33.
46. Ong CK, Subimerb C, Pairojkul C, et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet. 2012;44:690-3.
47. Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47:1003-10.
48. Olszewski K, Barsotti A, Feng XJ, et al. Inhibition of glucose transport synergizes with chemical or genetic disruption of mitochondrial metabolism and suppresses TCA cycle-deficient tumors. Cell Chem Biol. 2022;29:423-35.e10.
49. Saisomboon S, Kariya R, Boonnate P, et al. Diminishing acetyl-CoA carboxylase 1 attenuates CCA migration via AMPK-NF-κB-snail axis. Biochim Biophys Acta Mol Basis Dis. 2023;1869:166694.
50. Tomacha J, Dokduang H, Padthaisong S, et al. Targeting fatty acid synthase modulates metabolic pathways and inhibits cholangiocarcinoma cell progression. Front Pharmacol. 2021;12:696961.
51. Panawan O, Silsirivanit A, Chang CH, et al. Establishment and characterization of a novel cancer stem-like cell of cholangiocarcinoma. Cancer Sci. 2023;114:3230-46.
52. Diehl FF, Sapp KM, Vander Heiden MG. The bidirectional relationship between metabolism and cell cycle control. Trends Cell Biol. 2024;34:136-49.
53. Rong Y, Darnell AM, Sapp KM, Vander Heiden MG, Spencer SL. Cells use multiple mechanisms for cell-cycle arrest upon withdrawal of individual amino acids. Cell Rep. 2023;42:113539.
54. Allen CNS, Arjona SP, Santerre M, Sawaya BE. Hallmarks of metabolic reprogramming and their role in viral pathogenesis. Viruses. 2022;14:602.
55. Shen X, Niu N, Xue J. Oncogenic KRAS triggers metabolic reprogramming in pancreatic ductal adenocarcinoma. J Transl Int Med. 2023;11:322-9.
56. Tiemin P, Peng X, Qingfu L, et al. Dysregulation of the miR-148a-GLUT1 axis promotes the progression and chemoresistance of human intrahepatic cholangiocarcinoma. Oncogenesis. 2020;9:19.
57. Thamrongwaranggoon U, Kuribayashi K, Araki H, et al. Lactic acidosis induces metabolic and phenotypic reprogramming in cholangiocarcinoma cells via the upregulation of thrombospondin-1. Cancer Sci. 2023;114:1541-55.
58. Thamrongwaranggoon U, Detarya M, Seubwai W, et al. Lactic acidosis promotes aggressive features of cholangiocarcinoma cells via upregulating ALDH1A3 expression through EGFR axis. Life Sci. 2022;302:120648.
59. Thonsri U, Seubwai W, Waraasawapati S, et al. Overexpression of lactate dehydrogenase A in cholangiocarcinoma is correlated with poor prognosis. Histol Histopathol. 2017;32:503-10.
60. Colyn L, Alvarez-Sola G, Latasa MU, et al. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming. J Exp Clin Cancer Res. 2022;41:183.
61. Liu J, Zhang C, Hu W, Feng Z. Tumor suppressor p53 and metabolism. J Mol Cell Biol. 2019;11:284-92.
62. Liu VM, Howell AJ, Hosios AM, Li Z, Israelsen WJ, Vander Heiden MG. Cancer-associated mutations in human pyruvate kinase M2 impair enzyme activity. FEBS Lett. 2020;594:646-64.
63. Israelsen WJ, Vander Heiden MG. Pyruvate kinase: function, regulation and role in cancer. Semin Cell Dev Biol. 2015;43:43-51.
64. Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41:211-8.
65. Liao M, Yao D, Wu L, et al. Targeting the Warburg effect: a revisited perspective from molecular mechanisms to traditional and innovative therapeutic strategies in cancer. Acta Pharm Sin B. 2024;14:953-1008.
66. Corti F, Nichetti F, Raimondi A, et al. Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: a review of current evidences and future perspectives. Cancer Treat Rev. 2019;72:45-55.
67. Tian LY, Smit DJ, Jücker M. The role of PI3K/AKT/mTOR signaling in hepatocellular carcinoma metabolism. Int J Mol Sci. 2023;24:2652.
68. Thamrongwaranggoon U, Seubwai W, Phoomak C, et al. Targeting hexokinase II as a possible therapy for cholangiocarcinoma. BBRC. 2017;484:409-15.
69. Thonsri U, Seubwai W, Waraasawapati S, et al. Antitumor effect of shikonin, a PKM2 inhibitor, in cholangiocarcinoma cell lines. Anticancer Res. 2020;40:5115-24.
70. Infantino V, Santarsiero A, Convertini P, Todisco S, Iacobazzi V. Cancer cell metabolism in hypoxia: role of HIF-1 as key regulator and therapeutic target. Int J Mol Sci. 2021;22:5703.
71. Courtnay R, Ngo DC, Malik N, Ververis K, Tortorella SM, Karagiannis TC. Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K. Mol Biol Rep. 2015;42:841-51.
72. Wicks EE, Semenza GL. Hypoxia-inducible factors: cancer progression and clinical translation. J Clin Invest. 2022;e159839:132.
73. Seubwai W, Kraiklang R, Wongkham C, Wongkham S. Hypoxia enhances aggressiveness of cholangiocarcinoma cells. Asian Pac J Cancer Prev 2012;13:53-8. Available from: https://journal.waocp.org/article_27145_9dfbf7f01173f0a9bed0e95ceb44fb22.pdf. [Last accessed on 9 Dec 2024].
74. Thongchot S, Yongvanit P, Loilome W, et al. High expression of HIF-1α, BNIP3 and PI3KC3: hypoxia-induced autophagy predicts cholangiocarcinoma survival and metastasis. Asian Pac J Cancer Prev. 2014;15:5873-8.
75. Chen Y, Xu X, Wang Y, et al. Hypoxia-induced SKA3 promoted cholangiocarcinoma progression and chemoresistance by enhancing fatty acid synthesis via the regulation of PAR-dependent HIF-1a deubiquitylation. J Exp Clin Cancer Res. 2023;42:265.
76. Tang J, Tang R, Gu P, Han J, Huang W, Xue F. Hsa_circ_0019054 up-regulates HIF1A through sequestering miR-340-5p to promote the tumorigenesis of intrahepatic cholangiocarcinoma. Hum Exp Toxicol. 2022;41:9603271221126494.
77. Hsu CC, Tseng LM, Lee HC. Role of mitochondrial dysfunction in cancer progression. Exp Biol Med. 2016;241:1281-95.
78. Senyilmaz D, Teleman AA. Chicken or the egg: Warburg effect and mitochondrial dysfunction. F1000Prime Rep. 2015;7:41.
79. Suwannakul N, Armartmuntree N, Thanan R, et al. Targeting fructose metabolism by glucose transporter 5 regulation in human cholangiocarcinoma. Genes Dis. 2022;9:1727-41.
80. Xu L, Li Y, Zhou L, et al. SIRT3 elicited an anti-Warburg effect through HIF1α/PDK1/PDHA1 to inhibit cholangiocarcinoma tumorigenesis. Cancer Med. 2019;8:2380-91.
81. Thonsri U, Wongkham S, Wongkham C, et al. High glucose-ROS conditions enhance the progression in cholangiocarcinoma via upregulation of MAN2A2 and CHD8. Cancer Sci. 2021;112:254-64.
82. Xu L, Wang L, Zhou L, et al. The SIRT2/cMYC pathway inhibits peroxidation-related apoptosis in cholangiocarcinoma through metabolic reprogramming. Neoplasia. 2019;21:429-41.
83. Sun L, Song L, Wan Q, et al. cMyc-mediated activation of serine biosynthesis pathway is critical for cancer progression under nutrient deprivation conditions. Cell Res. 2015;25:429-44.
84. Colyn L, Bárcena-Varela M, Álvarez-Sola G, et al. Dual targeting of G9a and DNA methyltransferase-1 for the treatment of experimental cholangiocarcinoma. Hepatology. 2021;73:2380-96.
85. Ferrer CM, Sodi VL, Reginato MJ. O-GlcNAcylation in cancer biology: linking metabolism and signaling. J Mol Biol. 2016;428:3282-94.
86. Minh G, Esquea EM, Young RG, Huang J, Reginato MJ. On a sugar high: role of O-GlcNAcylation in cancer. J Biol Chem. 2023;299:105344.
87. Phoomak C, Silsirivanit A, Wongkham C, et al. Overexpression of O-GlcNAc-transferase associates with aggressiveness of mass-forming cholangiocarcinoma. Asian Pac J Cancer Prev 2012;13:101-5. Available from: https://journal.waocp.org/article_27153_c1ed4aa079225da4d304049e5bfd1939.pdf. [Last accessed on 9 Dec 2024].
88. Phoomak C, Silsirivanit A, Park D, et al. O-GlcNAcylation mediates metastasis of cholangiocarcinoma through FOXO3 and MAN1A1. Oncogene. 2018;37:5648-65.
89. Phoomak C, Park D, Silsirivanit A, et al. O-GlcNAc-induced nuclear translocation of hnRNP-K is associated with progression and metastasis of cholangiocarcinoma. Mol Oncol. 2019;13:338-57.
90. Khawkhiaw K, Chomphoo S, Kunprom W, et al. Involvement of interleukin-1β in high glucose-activated proliferation of cholangiocarcinoma. Transl Gastroenterol Hepatol. 2024;9:36.
91. Kongpetch S, Jusakul A, Lim JQ, et al. Lack of targetable FGFR2 fusions in endemic fluke-associated cholangiocarcinoma. JCO Glob Oncol. 2020;6:628-38.
92. Liu C, Xuan LQ, Li K, et al. Shikonin inhibits cholangiocarcinoma cell line QBC939 by regulating apoptosis, proliferation, and invasion. Cell Transplant. 2021;30:963689720979162.
93. Qian Z, Hu W, Lv Z, et al. PKM2 upregulation promotes malignancy and indicates poor prognosis for intrahepatic cholangiocarcinoma. Clin Res Hepatol Gastroenterol. 2020;44:162-73.
94. Yu W, Zeng F, Xiao Y, et al. Targeting PKM2 improves the gemcitabine sensitivity of intrahepatic cholangiocarcinoma cells via inhibiting β-catenin signaling pathway. Chem Biol Interact. 2024;387:110816.
95. Tang D, Xu L, Zhang M, et al. Metformin facilitates BG45-induced apoptosis via an anti-Warburg effect in cholangiocarcinoma cells. Oncol Rep. 2018;39:1957-65.
96. Zhang Y, Li Q, Huang Z, et al. Targeting glucose metabolism enzymes in cancer treatment: current and emerging strategies. Cancers. 2022;14:4568.
97. Molenaar RJ, Coelen RJS, Khurshed M, et al. Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours. BMJ Open. 2017;7:e014961.
98. Khurshed M, Molenaar RJ, van Linde ME, et al. A phase Ib clinical trial of metformin and chloroquine in patients with IDH1-mutated solid tumors. Cancers. 2021;13:2474.
99. Mohan A, Griffith KA, Wuchu F, et al. Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: preclinical evaluation and phase Ib multicenter clinical trial (BilT-04). Clin Cancer Res. 2023;29:2394-400.
100. Sahai V, Griffith KA, Zhen DB, et al. Phase 1b/2 results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- devimistat as first-line therapy for patients with advanced biliary tract cancer (BilT-04). JCO. 2024;42:4116.
101. Tsang ES, O'kane GM, Knox JJ, Chen EX. A phase II study of olaparib and durvalumab in patients with IDH-mutated cholangiocarcinoma. JCO. 2023;41:4099.
